论文部分内容阅读
目的探讨罗格列酮辛伐他汀对兔动脉粥样硬化形成的影响。方法40只日本大耳白兔随机分为五组,正常对照组、高脂模型组、罗格列酮组、辛伐他汀组、罗格列酮+辛伐他汀组,每组8只。A组(正常对照组):普通颗粒饲料喂饲150g,日二次,10周。B组(高脂模型组):高脂饲料(1%胆固醇+8%猪油+普通颗粒饲料)150g,日二次,10周。C组(罗格列酮组):高脂饲料喂饲10周,从喂饲高脂饲料起,给予口服罗格列酮0.5mg/kg/日。D组(辛伐他汀组):高脂饲料喂饲10周,从喂饲高脂饲料起,给予口服辛伐他汀2.5mg/kg/日。E组(罗格列酮+辛伐他汀组):高脂饲料喂饲10周,从喂饲高脂饲料起,给予口服罗格列酮0.5mg/kg/日+辛伐他汀2.5mg/kg/日。实验结束后获取血浆和主动脉全长标本进行生化和病理分析。结果罗格列酮组、辛伐他汀组、罗格列酮+辛伐他汀组三组C-反应蛋白(CRP)明显低于高脂模型组P<0.01,罗格列酮组、罗格列酮+辛伐他汀组非对称二甲基精氨酸(ADMA)血浆水平低于高脂模型组P<0.01,罗格列酮组、辛伐他汀组、罗格列酮+辛伐他汀组三组斑块面积占纵剖面主动脉面积之比明显小于高脂模型组。结论过氧化物酶增殖物激活受体激动剂罗格列酮以及他汀类药物辛伐他汀通过抑制炎症反应可以防治动脉硬化的发生发展,具有协同作用。
Objective To investigate the effect of simvastatin on the formation of atherosclerosis in rabbits. Methods Forty Japanese white rabbits were randomly divided into five groups: normal control group, high fat model group, rosiglitazone group, simvastatin group and rosiglitazone + simvastatin group. Group A (normal control group): ordinary pellet feed 150g, day two, 10 weeks. Group B (high fat model group): high fat diet (1% cholesterol + 8% lard + ordinary pellet feed) 150g, twice daily for 10 weeks. Group C (rosiglitazone group): high-fat diet for 10 weeks, fed with high-fat diet, given oral rosiglitazone 0.5mg / kg / day. Group D (simvastatin group): The high-fat diet was fed for 10 weeks and given simvastatin 2.5 mg / kg / day from the high-fat diet. Group E (rosiglitazone + simvastatin group): The high-fat diet was fed for 10 weeks. From the high-fat diet fed, oral administration of rosiglitazone 0.5 mg / kg / day plus simvastatin 2.5 mg / kg /day. After the experiment, the full-length specimens of plasma and aorta were obtained for biochemical and pathological analysis. Results The levels of C-reactive protein (CRP) in rosiglitazone group, simvastatin group and rosiglitazone + simvastatin group were significantly lower than those in high fat model group (P <0.01), rosiglitazone group, The plasma level of asymmetric dimethylarginine (ADMA) in ketones + simvastatin group was lower than that in high fat model group (P <0.01), rosiglitazone group, simvastatin group, rosiglitazone + simvastatin group Group plaque area accounted for longitudinal section of aortic area ratio was significantly less than the high-fat model group. Conclusion Peroxisome proliferator-activated receptor agonist rosiglitazone and statin simvastatin can prevent and treat the occurrence and development of atherosclerosis by inhibiting the inflammatory reaction and have a synergistic effect.